2. Academic Validation
  3. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

  • Medchemcomm. 2017 Jan 26;8(3):621-624. doi: 10.1039/c6md00643d.
Lian-Xiang Luo 1,  Xing-Xing Fan 1,  Ying Li 1,  Xia Peng 2,  Yin-Chun Ji 2,  Wendy Wen-Luan Hsiao 1,  Liang Liu 1,  Elaine Lai-Han Leung 1,  Xiao-Jun Yao 1
Affiliations

Affiliations

  • 1 State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute For Applied Research in Medicine and Health , Macau University of Science and Technology , Macau SAR , China . Email: lliu@must.edu.mo ; Email: lhleung@must.edu.mo ; Email: xjyao@must.edu.mo ; ; Tel: +853 8897 2438.
  • 2 State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academic of Sciences , Shanghai , China.
PMID: 30108778 DOI: 10.1039/c6md00643d
Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate Cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung Cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell Apoptosis.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z